Clinical Trial Update: Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating azacitidine and rituximab-GDP immunochemotherapy for relapsed/refractory diffuse large B-cell lymphoma and relapsed/refract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• rituximab-GDP (rituximab-GDP)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Diffuse Large B Cell Lymphoma, Relapsed Non Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN